Rajendra Kumar1, Meena Kumar2, Kavin Malhotra3, Shreyaskumar Patel3,4. 1. Department of Diagnostic Imaging, UT MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1475, Houston, TX, 77030, USA. rajkumar@mdanderson.org. 2. Department of Diagnostic Imaging, Section of Nuclear Medicine, Veterans Administration Hospital, 1660 S. Columbian Way, Seattle, WA, 98108, USA. 3. Victoria Radiology Associates, 2701 Hospital Drive, Victoria, TX, 77901, USA. 4. Department of Sarcoma Medical Oncology, UT MD Anderson Cancer Center, 1400 - Holcombe Blvd., Unit # 450, Houston, TX, 77030, USA.
Abstract
PURPOSE OF REVIEW: Osteosarcoma is mostly seen in bones of children and young adults. When it occurs in older persons, the tumor is considered secondary usually complicating Paget disease or irradiated bone. However, there is a second incidence peak of primary osteosarcoma later in life when these tumors occur de novo. This article describes the clinical, imaging, and treatment of POS in older patients, including demographic data of patients from our institution. FINDINGS: We present our experience with 920 cases of osteosarcoma that were seen between 1984 and 2003 at the University of Texas MD Anderson Cancer Center in Houston, TX, USA. Among the 868 primary osteosarcoma of bones, there were 100 (11.52%), which comprised 69% of the tumors in patients over the age of 50 years. Older patients with primary osteosarcoma tend to have relatively more common axial skeleton involvement, have more distant disease, and are difficult to treat because of concomitant comorbidities. Despite that, most adult patients treated with chemotherapy have shown good results with longer disease-free survival. A lytic bone lesion seen in radiographs of elderly patients should include primary osteosarcoma among differential diagnoses. Radical surgery and chemotherapy seem to ensure long-term disease-free survival in most cases. The elderly patients with POS in pelvis, spine, and upper extremities and those with distant disease (metastases) have worse prognosis.
PURPOSE OF REVIEW: Osteosarcoma is mostly seen in bones of children and young adults. When it occurs in older persons, the tumor is considered secondary usually complicating Paget disease or irradiated bone. However, there is a second incidence peak of primary osteosarcoma later in life when these tumors occur de novo. This article describes the clinical, imaging, and treatment of POS in older patients, including demographic data of patients from our institution. FINDINGS: We present our experience with 920 cases of osteosarcoma that were seen between 1984 and 2003 at the University of Texas MD Anderson Cancer Center in Houston, TX, USA. Among the 868 primary osteosarcoma of bones, there were 100 (11.52%), which comprised 69% of the tumors in patients over the age of 50 years. Older patients with primary osteosarcoma tend to have relatively more common axial skeleton involvement, have more distant disease, and are difficult to treat because of concomitant comorbidities. Despite that, most adult patients treated with chemotherapy have shown good results with longer disease-free survival. A lytic bone lesion seen in radiographs of elderly patients should include primary osteosarcoma among differential diagnoses. Radical surgery and chemotherapy seem to ensure long-term disease-free survival in most cases. The elderly patients with POS in pelvis, spine, and upper extremities and those with distant disease (metastases) have worse prognosis.
Entities:
Keywords:
Osteosarcoma; Primary osteosarcoma; Primary osteosarcoma in adults; Primary osteosarcoma in older persons
Authors: Mark L Kayton; Andrew G Huvos; Jennifer Casher; Sara J Abramson; Nancy S Rosen; Leonard H Wexler; Paul Meyers; Michael P LaQuaglia Journal: J Pediatr Surg Date: 2006-01 Impact factor: 2.545
Authors: G Bacci; S Ferrari; D Donati; A Longhi; F Bertoni; M Di Fiore; A Comandone; M Cesari; M Campanacci Journal: Oncol Rep Date: 1998 Sep-Oct Impact factor: 3.906
Authors: Yining Xu; Teng Yao; Haonan Ni; Rujie Zheng; Kangmao Huang; Yizhen Huang; Jun Gao; Di Qiao; Shuying Shen; Jianjun Ma Journal: Front Cell Dev Biol Date: 2021-04-22
Authors: Nil A Schubert; Caitlin D Lowery; Guillaume Bergthold; Jan Koster; Thomas F Eleveld; Ana Rodríguez; David T W Jones; Gilles Vassal; Louis F Stancato; Stefan M Pfister; Hubert N Caron; Jan J Molenaar Journal: Eur J Cancer Date: 2020-03-27 Impact factor: 9.162